Vivek A Rudrapatna
Overview
Explore the profile of Vivek A Rudrapatna including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
246
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rudrapatna V, Wang T, Vazirnia P, Wang K, Alhalel N, Slatter S, et al.
medRxiv
. 2025 Jan;
PMID: 39867357
Background: Healthcare is a major contributor to global greenhouse gas emissions. Colorectal cancer (CRC) screening is one of the most widely used healthcare services in the US, indicated for approximately...
2.
Reducing diagnostic delays in acute hepatic porphyria using health records data and machine learning
Bhasuran B, Schmolly K, Kapoor Y, Jayakumar N, Doan R, Amin J, et al.
J Am Med Inform Assoc
. 2024 Jul;
32(1):63-70.
PMID: 38946554
Background: Acute hepatic porphyria (AHP) is a group of rare but treatable conditions associated with diagnostic delays of 15 years on average. The advent of electronic health records (EHR) data...
3.
Silverman A, Bhasuran B, Mosenia A, Yasini F, Ramasamy G, Banerjee I, et al.
Inflamm Bowel Dis
. 2024 Mar;
31(3):665-670.
PMID: 38533919
Background: The Mayo endoscopic subscore (MES) is an important quantitative measure of disease activity in ulcerative colitis. Colonoscopy reports in routine clinical care usually characterize ulcerative colitis disease activity using...
4.
Patel P, Zhang A, Bhasuran B, Ravindranath V, Heyman M, Verstraete S, et al.
J Pediatr Gastroenterol Nutr
. 2024 Mar;
78(5):1126-1134.
PMID: 38482890
Objectives: Vedolizumab (VDZ) and ustekinumab (UST) are second-line treatments in pediatric patients with ulcerative colitis (UC) refractory to antitumor necrosis factor (anti-TNF) therapy. Pediatric studies comparing the effectiveness of these...
5.
Silverman A, Sushil M, Bhasuran B, Ludwig D, Buchanan J, Racz R, et al.
Clin Pharmacol Ther
. 2024 Mar;
115(6):1391-1399.
PMID: 38459719
Outpatient clinical notes are a rich source of information regarding drug safety. However, data in these notes are currently underutilized for pharmacovigilance due to methodological limitations in text mining. Large...
6.
Rudrapatna V, Ravindranath V, Arneson D, Mosenia A, Butte A, Wang S
medRxiv
. 2023 Nov;
PMID: 37986977
Background: Meta-analyses have found anti-TNF drugs to be the best treatment, on average, for Crohn's disease. We performed a subgroup analysis to determine if it is possible to achieve more...
7.
Rudrapatna V, Ravindranath V, Arneson D, Mosenia A, Butte A, Wang S
BMC Med Res Methodol
. 2023 Oct;
23(1):218.
PMID: 37789257
Background: The advent of clinical trial data sharing platforms has created opportunities for making new discoveries and answering important questions using already collected data. However, existing methods for meta-analyzing these...
8.
Silverman A, Sushil M, Bhasuran B, Ludwig D, Buchanan J, Racz R, et al.
medRxiv
. 2023 Sep;
PMID: 37732220
Background And Aims: Outpatient clinical notes are a rich source of information regarding drug safety. However, data in these notes are currently underutilized for pharmacovigilance due to methodological limitations in...
9.
Bhasuran B, Schmolly K, Kapoor Y, Jayakumar N, Doan R, Amin J, et al.
medRxiv
. 2023 Sep;
PMID: 37693437
Importance: Acute Hepatic Porphyria (AHP) is a group of rare but treatable conditions associated with diagnostic delays of fifteen years on average. The advent of electronic health records (EHR) data...
10.
Wang M, Slatter S, Sussell J, Lin C, Ogale S, Datta D, et al.
Target Oncol
. 2023 Jun;
18(4):571-583.
PMID: 37341856
Background: Randomized trials have demonstrated that anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) can be safe and efficacious treatments for patients with ALK-positive advanced non-small-cell lung cancer (aNSCLC). However,...